FDA Approves Lilly’s Once-Weekly Insulin Onswik, Challenging Novo’s Awiqli
FDA clears Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It may cut 300+ shots a year and now competes with Novo’s Awiqli.
FDA clears Lilly’s Onswik, a once-weekly basal insulin for adults with type 2 diabetes. It may cut 300+ shots a year and now competes with Novo’s Awiqli.
Investors are watching liability and damages in Nektar’s breach case against Lilly, a key swing factor for the Rezpeg program. Analysts still see damages as the hard issue.
Viking reported 16–19% weight loss at week 21 and strong maintenance on monthly dosing. GI side effects in the later phase looked like placebo.
Distant 2030 goals failed to ease concerns over patents and Lilly.
Twist Bioscience and Ginkgo Datapoints join Eli Lilly’s TuneLab to pair lab testing with AI for faster antibody drug discovery.
Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.